Esperion Therapeutics | ESPR - Ativo Circulante





Ativo Circulante Alterar Data
AbbVie USD 29.06B 523M 2025-12
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
Alterity Therapeutics Limited AUD 37.91M 15.92M 2025-12
Amarin USD 626.02M 23.87M 2026-03
Amgen USD 31.48B 2.42B 2026-03
Biogen USD 9.19B 216.3M 2026-03
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
Cipla INR 249.18B 16.3B 2025-09
CSL USD 11.85B 1000K 2025-12
Cytokinetics USD 839.46M 77.51M 2026-03
Daiichi Sankyo JPY 2.1T 218.5B 2025-12
Eli Lilly USD 54.84B 794M 2026-03
Esperion Therapeutics USD 462.57M 102.11M 2025-12
Geron USD 520.27M 2.07M 2025-12
Grifols EUR 5.96B 316.31M 2025-12
Halozyme Therapeutics USD 825.21M 503.54M 2025-12
Heron Therapeutics USD 238.07M 8.67M 2025-12
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
Merck USD 35.02B 8.5B 2026-03
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Moderna USD 5.77B 774M 2026-03
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Pfizer USD 42.82B 76M 2026-03
PTC Therapeutics USD 2.27B 266.14M 2025-12
Puma Biotechnology USD 143.58M 7M 2025-09
Regeneron Pharmaceuticals USD 18.21B 187.3M 2026-03
Sanofi EUR 30.16B 789M 2026-03
Sarepta Therapeutics USD 2.54B 184.37M 2025-12
United Therapeutics USD 3.7B 208.5M 2025-12
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12